Prospective evaluation of bone markers, parathormone and 1,25-.sub.2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
Health aspects, Research, Physiological aspects, Genetic aspects, Osteoporosis, Care and treatment, Patient outcomes, Diagnosis, HIV patients, Highly active antiretroviral therapy, HIV infection, Biological markers